TORONTO, ON / ACCESSWIRE / June 29, 2017 / Theralase Technologies Inc. (''Theralase®'' or the ''Company'') (TSX-V: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (''PDCs'') to destroy cancer, is pleased to announce that the Theralase therapeutic laser technology has been proven effective in the treatment of arthritis in recently published animal research.
The research was published online May 30, 2017, in Lasers in Medical Science, entitled, ''Low-intensity laser therapy efficacy evaluation in FVB mice subjected to acute and chronic arthritis," authored by Joào Paulo Mardegan Issa, Bianca Ferreira Trawitzki, Edilson Ervolino, Ana Paula Macedo, and Lothar Lilge.
An abstract to the publication is available at the link below:
https://link.springer.com/article/10.1007/s10103-017-2235-5
Rheumatoid arthritis, a chronic inflammatory disorder, has a high prevalence in the population and, while therapy is available, it often requires injection of drugs causing discomfort to patients. This study was used to evaluate the clinical and histological effect of Low-Intensity Laser Therapy (''LILT'') as an alternative treatment, in a mouse model of both acute and chronic inflammation.
LILT delivered by either 660, 808, or superpulsed 905 nanometer (''nm'') laser light and tissue response was evaluated on the following criteria: clinical symptoms, histological analysis of inflammatory infiltrate and damage to the articular surfaces.
The results demonstrate that LILT wavelength selection depends on the arthritic condition being treated. Superpulsed 905 nm laser light demonstrated better results for an anti-inflammatory effect in acute arthritis, while 660 nm laser light showed better results in chronic arthritis.
For acute inflammation, a single treatment using lasers with an intermediate or long wavelength was sufficient to promote an anti-inflammatory effect and control articular resorption (joint degeneration); double treatment on sequential days in cases of acute inflammation was not beneficial. For chronic inflammation, a treatment plan comprising three sessions with an interval of 1 day between them was sufficient to eliminate the clinical signs and to control articular resorption.
Roger Dumoulin-White, President and CEO of Theralase, stated, ''The Theralase therapeutic technology utilizes both superpulsed 905 and 660 nm laser light wavelengths and based on the latest published research are considered optimal wavelengths to treat arthritis in both an acute and chronic model. The publication also supports Theralase's methodology of treating patients every other day. It is this type of preclinical research, which helps increase adoption of Theralase laser therapy by main stream medicine to allow healthcare practitioners the opportunity to effectively treat, a devastating disease, such as arthritis.''
About Theralase Technologies Inc.
Theralase Technologies Inc. (''Theralase®'' or the ''Company'') (TSX-V: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (''TLT'') Division designs, manufactures, markets, and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase's Photo Dynamic Therapy (''PDT'') Division researches and develops specially designed molecules called Photo Dynamic Compounds (''PDCs''), which localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com.
This news release contains ''forward-looking statements'' which reflect the current expectations of management of the Corporation's future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as "may," "would," "could," "should," "will," "anticipate," "believe," "plan," "expect," "intend," "estimate," ''potential for'' and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
[email protected]
www.theralase.com
SOURCE: Theralase Technologies Inc.